Nov 04, 2019 / 09:30PM GMT
Operator
Welcome to the Acorda Therapeutics third quarter 2019 updates. (Operator Instructions) Please be advised that this call is being taped at the company's request.
I will now introduce your host for today's call, Felicia Vonella, Vice President of Investor Relations at Acorda. Please go ahead.
Felicia Vonella - Acorda Therapeutics, Inc. - VP of IR
Good afternoon, everyone. Before we begin, let me remind everyone our presentation will contain forward-looking statements. Detailed disclosures can be found in our SEC filings, which are public, and we encourage you to refer to those filings. I will now pass the call over to Ron Cohen, our CEO.
Ron Cohen - Acorda Therapeutics, Inc. - Founder, CEO, President & Director
Good afternoon, everyone. Thanks, Felicia. This slide highlights the key events in the third quarter. As you all know, the initial stage of the launch of INBRIJA has been more gradual than expected. However, multiple inputs continue to support our conviction that INBRIJA will be a substantial product
Q3 2019 Acorda Therapeutics Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot